Clinical trial
Doxorubicin Pharmacokinetic (PK) Study
NCT00124956 · Boston Children's Hospital, Other · Withdrawn
Key facts
| NCT number | NCT00124956 |
|---|---|
| Title | Doxorubicin Pharmacokinetic (PK) Study |
| Official title | Impact of Body Composition on Pharmacokinetics of Doxorubicin in Pediatric Patients |
| Lead sponsor | Boston Children's Hospital, Other |
| Collaborators | Glaser Pediatric Research Network Elizabeth Glaser Pediatric AIDS Foundation |
| Status | Withdrawn |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Cancer |
| Intervention type | Drug |
| Interventions | Doxorubicin |
| Enrollment | 0 |
| Start date | Jun 1, 2003 |
| First posted | Jul 29, 2005 |
| Last update posted | Sep 11, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: